Back

Xenetic agrees to buy Santersus in all-stock deal, plans Nasdaq rebrand

Verifying
  • Xenetic agreed to acquire Santersus through an all-stock share exchange.
  • Shares fell 40.98% to $2.52 at Wednesday’s publication, Benzinga Pro data showed.
  • The combined company plans to become Santersus Bio and use ticker SNTS.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.